Antibody Titer and Specificity Analysis Service
CD BioGlyco offers a specialized antibody titer and specificity analysis service, providing researchers with deep insights into the efficacy and precision of mRNA-encoded antigens by measuring the concentration (titer) and binding precision (specificity) of the resulting antibodies. Whether you are developing a prophylactic vaccine for infectious diseases or a therapeutic vaccine for oncology, understanding how effectively your mRNA construct triggers the production of targeted antibodies is a critical quality attribute (CQA). Our expert team leverages high-end bioanalytical tools to ensure that your vaccine candidates elicit a robust, specific, and long-lasting immune response.
At CD BioGlyco, our service covers the full spectrum of antibody characterization required during the preclinical stages of mRNA vaccine development. Our analysis focuses on several key sub-substances and parameters:
Our experts collaborate with you to define the specific requirements of your study, including the choice of antigens, target species, and the desired depth of kinetic analysis.
Upon receiving serum, plasma, or purified antibody samples, we perform standardized preparation and dilution protocols to ensure optimal performance in the selected assay.
We develop or adapt assays specifically for your mRNA-encoded antigen. This includes optimizing coating concentrations for ELISA or sensor loading for SPR to ensure a broad dynamic range and high sensitivity.
Using serial dilutions, we generate comprehensive binding curves and calculate EC50 or ED50 values. We also perform isotype profiling to characterize the breadth of the immune response.
We conduct detailed specificity tests, including competition assays and cross-reactivity screening. For lead candidates, we perform full kinetic profiling to determine the binding strength and stability of the antibody-antigen complex.
The results are rigorously analyzed using advanced statistical software. You receive a detailed report including raw data, titration curves, kinetic constants, and a professional summary of the findings.
DoI: 10.1186/s41182-024-00635-y
Journal: Tropical Medicine Health
IF: 3.7
Published: 2024
Results: This exploratory study evaluates the diagnostic accuracy and antibody titer profile of the indirect immunoperoxidase assay (IIP) for SARS-CoV-2. Using six SARS-CoV-2 variants (including wild type-A and Omicron subvariants) as whole-cell antigens, the IIP showed high IgG accuracy (84.8%) at a 1:80 cutoff, with sensitivity (82.2%) and specificity (94.7%) comparable to ELISA (AUC ~0.90 for both). Most participants had the highest IgG/IgM titers against wild type-A. Post-two vaccinations, 35/36 volunteers tested positive via IIP and ELISA, and 34 via lateral flow assay (LFA). Factors linked to high IIP IgG titers (>1:640) in patients included age (50-64 years), ≥14 days post-symptom onset, ≥7 days post-second vaccination, and no immunosuppressant use. The IIP's affordability and comparable accuracy support its use in resource-limited settings, though further research on antibody protective effects is needed.
Fig.1 IgG ELISA OD ratio and IgG titer by IIP among COVID-19 patients and controls. (Katoh, et al., 2024)
mRNA Vaccine Immunogenicity Studies
Quantifying the antibody response in various animal models or clinical trial participants to confirm the protective potential and dosing requirements of new mRNA vaccine candidates.
Preclinical Safety and Toxicology
Monitoring for ADAs to assess the safety profile and potential for hypersensitivity reactions toward the mRNA delivery system or the expressed protein.
Antigen Design Optimization
Using specificity and affinity data to refine the mRNA sequence and antigen structure, ensuring that the most effective epitopes are being targeted by the immune system.
Infectious Disease Research
Assessing the cross-reactivity of vaccine-induced antibodies against emerging variants or different strains of a pathogen is a critical step for developing pan-protective mRNA vaccines.
High Sensitivity and Broad Dynamic Range
Our optimized platforms detect trace levels of antibodies, ensuring that early-stage immune responses are not missed during the vaccine development process.
Orthogonal Validation Approach
By combining ELISA with kinetic methods like SPR, we provide a more complete and validated picture of the antibody response than single-platform analysis.
mRNA-Specific Bioanalysis Expertise
CD BioGlyco understands the unique challenges of analyzing antibodies generated from in vivo-expressed proteins compared to traditional protein vaccines.
Customized Assay Solutions
We do not believe in a one-size-fits-all approach; every assay is tailored to the specific antigens and experimental goals of your unique mRNA program.
The team at CD BioGlyco provided exceptional support for our mRNA-based influenza vaccine program. Their antibody titer and specificity analysis were remarkably precise, allowing us to differentiate the immune response across several viral variants.
— D.E., Biopharmaceutical Company
Understanding the IgG1/IgG2a ratio was critical for our safety assessment, and CD BioGlyco delivered the data well within our tight deadlines. Their expertise in mRNA bioanalysis is evident.
— A.R., Vaccine Research Institute
They developed a custom assay for our specific mRNA-LNP formulation that provided the sensitivity we couldn't find elsewhere. Highly recommended for any complex bioanalytical needs.
— E.Y., Stealth-mode Biotech
CD BioGlyco is your dedicated partner for advancing the next generation of mRNA-based therapeutics. By providing world-class antibody titer and specificity analysis, we help you bridge the gap between mRNA design and proclinical efficacy. Please feel free to contact us for more information and to discuss your project.
Reference
